BRAF and melanoma: The relevant data on ADRs for the dabrafenib/trametinib combination were available only from the COMBI-d trial, a randomized double-blind phase III trial evaluating dabrafenib/trametinib versus placebo/trametinib in previously untreated patients with BRAF-mutant melanoma [16,18].